Health Care · Dental Equipment & Supplies

XRAY DENTSPLY SIRONA Inc SEC Filings & Insider Trading Activity 2026

company
CIK 818479100 filings

XRAY at a glance

DENTSPLY SIRONA Inc (XRAY, SEC CIK 818479) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), DENTSPLY SIRONA Inc (XRAY) reported revenue of $3.7 billion (down 3.0% from FY2024) and a net loss of $598.0 million. Diluted EPS was -$3.00.
  • As of September 30, 2026, 37 institutional investment managers tracked by SignalX reported holding DENTSPLY SIRONA Inc (XRAY) shares worth $831.3 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by HOSEIN CLYDE on June 15, 2026 of 6,500 shares at $9.98 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$3.7B
−3.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
37 funds
$831.3M · +2 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 net sales down 5.2% YoY; segment revenue amounts not visible in provided table
  • Gross margin 52.9% vs 48.8% YoY; SG&A margin 43.4% vs 39.4%
  • Wellspect best segment, sales up 4.1% constant currency; OIS worst, down 7.2%
  • Operating cash flow increased, aided by $47M tariff refunds and lower receivables
  • Outlook: $165M-$185M 2026 capex; macro, tariffs, inflation and distributor inventory headwinds

Risk Factors

  • No material changes from the 2025 Form 10-K risk factors
  • Carried-forward risks include regulatory, operational, competitive, market, and financial exposures disclosed in the 2025 Form 10-K

AI summary of the XRAY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results for the quarter ended September 30, 2026
  • Press release Exhibit 99.1 contains the financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 sales $836M, down 7.6% YoY, with declines across three core segments; Wellspect grew 10.1%
  • Adjusted EPS $0.29, down 29.4%, and adjusted EBITDA margin 17.3% vs 18.4%, indicating weaker operating leverage
Filed Oct 9, 2026Full analysis →

Item 2.03: Creation of a Direct Financial Obligation

  • Note Purchase Agreement Amendments and Third Amendment to Credit Agreement create or modify debt obligations
  • Terms, borrowing amounts, interest rates and maturities require review of Item 1.01 for financing impact

Item 1.01: Entry into a Material Definitive Agreement

  • Lenders approved covenant relief through September 30 and December 31, 2026, raising permitted total and senior leverage ratios
  • EBITDA addback for specified cash charges, supporting covenant compliance during fiscal 2026
Filed Aug 7, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 results for quarter ended June 30, 2026
  • Press release Exhibit 99.1 contains the company’s financial results

Item EX-99.1: Item EX-99.1

  • Q2 sales $898M, down 4.1% reported and 6.3% constant currency, signaling continued top-line pressure
  • GAAP EPS $0.18 versus $(0.22), while adjusted EPS held at $0.52 despite adjusted EBITDA declining 3.3% to $190M

AI summaries of XRAY 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for XRAY

Don't miss the next XRAY filing

  • Alerts as it files. A push when XRAY files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut XRAY, by share count.
  • Ask anything. An AI agent that reads every XRAY filing and answers with sources.

XRAY alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Czerney KevinFNov 11, 2026-
Barton-Brobst Lindi ReneFNov 11, 2026$9.76
MAZELSKY JONATHAN JAYASep 30, 2026$9.03
Fortson John C.AAug 10, 2026-
Fortson John C.AAug 10, 2026-
Frohning Andrea L.FAug 7, 2026$12.12
MAZELSKY JONATHAN JAYAJun 30, 2026$10.56
HOSEIN CLYDEBuyJun 15, 2026$9.98

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$3.8B$3.7B
Gross Profit-$2.0B$1.8B
Operating Income--$879.0M-$422.0M
Net Income--$910.0M-$598.0M
Gross Margin-51.6%50.0%
Op. Margin--23.2%-11.5%
Net Margin--24.0%-16.3%
Balance Sheet
Total Assets$7.4B$5.8B$5.4B
Equity$3.3B$1.9B$1.3B
ROE--46.9%-44.7%
Per Share
EPS$-0.62$-4.48$-3.00
Cash Flow
Operating CF$377.0M$461.0M$235.0M

Source: XBRL data in DENTSPLY SIRONA Inc (XRAY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate XRAY share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
XRAY shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202637$831.3M
Q2 202635$983.0M
Q1 202633$839.6M
Q4 202531$898.6M
Q3 202532$1.14B
Q2 202532$1.58B
Q1 202529$936.5M
Q4 202427$951.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 256 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

XRAY filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
4Nov 13, 2026--
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KOct 9, 2026Analysis-
4Oct 2, 2026--
4Aug 12, 2026--
4Aug 11, 2026--
8-KAug 7, 2026Analysis-
10-QAug 6, 2026-
8-KAug 6, 2026Analysis-
4Jul 1, 2026--
4Jun 18, 2026--
4Jun 16, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 11, 2026--
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-

Related Health Care companies

All Health Care →

XRAY SEC filings: frequently asked questions

Which institutions hold XRAY stock?

As of September 30, 2026, the largest DENTSPLY SIRONA Inc (XRAY) holders among the 13F filers tracked by SignalX were BlackRock ($231.5 million), AQR Capital Management ($104.8 million), Vanguard Portfolio Management LLC ($101.0 million), State Street Corp ($81.8 million), Vanguard Capital Management LLC ($80.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was XRAY's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), DENTSPLY SIRONA Inc (XRAY) reported revenue of $3.7 billion (down 3.0% from FY2024) and a net loss of $598.0 million. Diluted EPS was -$3.00. The figures come from the XBRL data in the 10-K.

What did XRAY report in its latest 8-K?

DENTSPLY SIRONA Inc (XRAY) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results for the quarter ended September 30, 2026.

What are the latest XRAY SEC filings?

DENTSPLY SIRONA Inc (XRAY) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.

What is XRAY's SEC CIK number?

DENTSPLY SIRONA Inc (XRAY)'s SEC Central Index Key (CIK) is 818479. EDGAR lists every XRAY filing under that number.

Ask anything about XRAY

The research agent reads XRAY's filings, financials, insider trades and 13F holders, then answers with sources.